| Dr Kyle W Griffin, MD | |
|
3800 S National Ave Ste 700, Springfield, MO 65807-5279 | |
| (417) 269-8817 | |
| (417) 269-8744 |
| Full Name | Dr Kyle W Griffin |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 3800 S National Ave Ste 700, Springfield, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710076948 | NPI | - | NPPES |
| 176566 | Other | MO | BCMO |
| 200659803 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2001014625 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cox Medical Centers | Springfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lester E Cox Medical Centers | 1254248917 | 262 |
News Archive
Finding a handful of cancer cells hiding among billions of blood cells in a patient sample can be like finding a needle in a haystack. In a new approach enabled by 3D-printed cell traps, researchers are removing the hay to expose the cancer cells.
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from University of Alabama at Birmingham scientists presented today in JCI Insight, a journal of the American Society for Clinical Investigation.
Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.
US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.
› Verified 3 days ago
| Entity Name | Advocates For A Healthy Community Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558303057 PECOS PAC ID: 5395653562 Enrollment ID: O20041109000631 |
News Archive
Finding a handful of cancer cells hiding among billions of blood cells in a patient sample can be like finding a needle in a haystack. In a new approach enabled by 3D-printed cell traps, researchers are removing the hay to expose the cancer cells.
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from University of Alabama at Birmingham scientists presented today in JCI Insight, a journal of the American Society for Clinical Investigation.
Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.
US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.
› Verified 3 days ago
| Entity Name | Lester E Cox Medical Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538334396 PECOS PAC ID: 1254248917 Enrollment ID: O20050624000293 |
News Archive
Finding a handful of cancer cells hiding among billions of blood cells in a patient sample can be like finding a needle in a haystack. In a new approach enabled by 3D-printed cell traps, researchers are removing the hay to expose the cancer cells.
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from University of Alabama at Birmingham scientists presented today in JCI Insight, a journal of the American Society for Clinical Investigation.
Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.
US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kyle W Griffin, MD Po Box 4046, Springfield, MO 65808-4046 Ph: (417) 269-5712 | Dr Kyle W Griffin, MD 3800 S National Ave Ste 700, Springfield, MO 65807-5279 Ph: (417) 269-8817 |
News Archive
Finding a handful of cancer cells hiding among billions of blood cells in a patient sample can be like finding a needle in a haystack. In a new approach enabled by 3D-printed cell traps, researchers are removing the hay to expose the cancer cells.
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.
Pulmospheres, three dimensional multicellular spheroids composed of lung cells from individual patients, were shown to be effective in predicting the efficacy of medications for idiopathic pulmonary fibrosis, according to findings from University of Alabama at Birmingham scientists presented today in JCI Insight, a journal of the American Society for Clinical Investigation.
Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.
US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.
› Verified 3 days ago
Shalvinder Kaur Seehra, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3525 E Battlefield St, Springfield, MO 65809 Phone: 417-269-1499 Fax: 417-269-1459 | |
Harwinder K Dhanoa, Family Medicine Medicare: Medicare Enrolled Practice Location: 1540 E Evergreen St, Springfield, MO 65803 Phone: 417-823-2900 | |
Thomas E Dahlberg, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3322 S Campbell Ave Ste T-1, Springfield, MO 65807 Phone: 417-220-4480 Fax: 417-414-0017 | |
Dr. John H Brown, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3231 S National Ave, Suite 280, Springfield, MO 65807 Phone: 417-885-0834 Fax: 417-888-6763 | |
Dr. Jay L Sparks, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3231 S National Ave, Suite 220, Springfield, MO 65807 Phone: 417-820-7450 Fax: 417-820-7455 | |
Dr. Conrad Mitchell Bajor, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1235 E Cherokee St, Springfield, MO 65804 Phone: 417-820-2600 | |
Dr. William Russell Detten, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1530 E Republic Rd, Springfield, MO 65804 Phone: 417-269-1362 Fax: 417-269-1372 |